Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Noel Gerard McElvaney (Dublin, Ireland), N. Gerard McElvaney, Kenneth R. Chapman, Jonathan Burdon, Eeva Piitulainen, Niels Seersholm, James Stocks, Robert Sandhaus, Oliver Vit, Michael Fries, Jonathan M. Edelman. LATE-BREAKING ABSTRACT: Long-term efficacy of A1-PI therapy in RAPID and RAPID extension trials. Eur Respir J 2015; 46: Suppl. 59, 285

Member's Comments

No comment yet.

Related content which might interest you: Safety of bi-weekly infusion of A1-PI augmentation therapy in RAPID Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Long-term efficacy of A1-PI therapy in RAPID and its extension study Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Safety of biweekly a1-antitrypsin treatment in the RAPID programme Source: Eur Respir J, 52 (5) 1800897; 10.1183/13993003.00897-2018 Year: 2018 LATE-BREAKING ABSTRACT: Cost-effectiveness of the LABA/LAMA dual bronchodilator QVA149 in a Swedish setting Source: Annual Congress 2013 –Health economics of airway diseases Year: 2013 One-year efficacy of aclidinium/formoterol fixed-dose combination in COPD patients: The AUGMENT COPD study Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Late Breaking Abstract - Prolonged azithromycin maintenance treatment in patients with COPD, a follow-up of the COLUMBUS trial Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019 LATE-BREAKING ABSTRACT: Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol/fluticasone combination (SFC) in patients with COPD: the LANTERN study Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 LATE-BREAKING ABSTRACT: LAVOLTA I and II: Results of 2 phase III studies to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016 Effect of exacerbations on lung density in alpha-1 antitrypsin deficiency: Subgroup analysis of the RAPID trial programme Source: International Congress 2018 – COPD phenotypes: a1 antitrypsin deficiency and beyond Year: 2018 Late Breaking Abstract - Dupilumab long-term safety and efficacy in patients with asthma: LIBERTY ASTHMA TRAVERSE Source: Virtual Congress 2020 – ALERT: Asthma in adults and children Year: 2020 INSTEAD: Randomized switch trial of indacaterol and salmeterol/fluticasone combination (SFC) in moderate COPD: Symptoms results Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 LATE-BREAKING ABSTRACT: The REACH study, a randomized controlled trial assessing the safety and effectiveness of the spiration valve system intra-bronchial therapy for severe emphysema Source: International Congress 2016 – Advancements in bronchoscopy Year: 2016 LATE-BREAKING ABSTRACT: The RENEW trial: Predictors of effectiveness of endobronchial coil therapy in patients with advanced emphysema Source: International Congress 2016 – Airway stenting and ablation Year: 2016 LATE-BREAKING ABSTRACT: Prevention of COPD exacerbation by lysozyme: A double-blind, randomized, placebo-controlled study Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015 Roflumilast for stable COPD: Meta-analysis of randomized controlled trials Source: International Congress 2014 – Clinical presentations Year: 2014 LATE-BREAKING ABSTRACT: Benralizumab reduces exacerbations in severe, uncontrolled asthma: Results of the phase III CALIMA trial Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016 Greatest International ANti-infective Trial (GIANT) – the German cohort: moxifloxacin treatment provides short- and long-term benefits in AECB patients Source: Annual Congress 2006 - Clinical aspects and treatment of lower respiratory infection in COPD patients Year: 2006 Late Breaking Abstract - RECEIVER trial: sustained use and improved outcomes with digitally supported COPD co-management Source: Virtual Congress 2021 – E-health for COVID-19 Year: 2021 LATE-BREAKING ABSTRACT: Oral corticosteroid-sparing effect of mepolizumab in severe eosinophilic asthma: the SIRIUS study Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment Year: 2014 Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020